175 results
8-K
EX-99.1
DYAI
Dyadic International Inc., DE
14 May 24
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
4:47pm
, fully funded research and development costs, and specified product milestones and royalties upon commercialization.
On February 21, 2024, the Company … as of December 31, 2023.
Revenue: Research and development revenue and license revenue for the three months ended March 31, 2024, decreased to approximately
8-K
EX-99.1
afvnpbx e1z
28 Mar 24
Dyadic Reports 2023 Full Year Results and Recent Company Progress
4:07pm
8-K
EX-99.1
mwygk1
8 Nov 23
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
4:09pm
8-K
EX-99.1
hpt16ehdjcp9bp 3a
9 Aug 23
Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
4:08pm
8-K
EX-99.1
3oqleyeq
10 May 23
Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
4:35pm
8-K
EX-10.1
nvg0ta yabt
12 Apr 23
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent
8:30am
8-K
EX-99.1
68xzu777ogc3zoe0lhl
29 Mar 23
Dyadic Reports 2022 Year End Results and Recent Company Progress
4:32pm
8-K
EX-99.1
rv8322 yw
10 Nov 22
Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments
4:06pm